文献速递肿瘤 PET/CT放射性药物与辐射防护

[68Ga]Ga-NOTA-H006用于5T4癌胚抗原无创PET显像的临床前评价及初步临床研究

Preclinical evaluation and pilot clinical study of [68Ga]Ga-NOTA-H006 for non-invasive PET imaging of 5T4 oncofetal antigen.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-10-08

本研究构建抗5T4纳米抗体H006并标记为[68Ga]Ga-NOTA-H006,在BxPC-3与MDA-MB-468荷瘤小鼠中行microPET/CT与离体生物分布,并在病理确诊的原发及转移肿瘤患者中于注射后1小时行PET/CT初步临床研究,显示该示踪剂可活体显示5T4表达。

要点

  • 人源化后H006对5T4保持高亲和力,[68Ga]Ga-NOTA-H006放化纯度大于98%。
  • BxPC-3荷瘤小鼠microPET/CT可清晰显示5T4表达,注射后60分钟肿瘤/血约3倍、肿瘤/肌肉约5倍。
  • 共注射1.5 mg/kg冷H006显著降低肿瘤摄取(p<0.0001)。

核心结论

  • 成功开发了可在活体显示5T4表达的[68Ga]Ga-NOTA-H006,为核医学无创研究5T4表达提供了机会。
  • 作者认为需进一步临床研究探索其在疾病进展和伴随诊断中的临床价值。

研究设计与样本

  • 临床前研究:经骆驼免疫构建VHH文库,经噬菌体展示生物淘选与周质提取物酶联免疫吸附试验筛选特异性VHH,偶联NOTA后标记,在BxPC-3与MDA-MB-468荷瘤小鼠中行microPET/CT与离体生物分布,并共注射冷VHH进行体内结合竞争。
  • 初步临床研究:对病理确诊的原发及转移肿瘤患者,注射示踪剂后1小时行PET/CT显像。

主要发现

  • 骆驼免疫后构建容量为1.2×1012菌落形成单位的文库,筛选出半数效应浓度为0.43 nM的Nb1-40。
  • 人源化后得到的H006对5T4保持高亲和力。
  • [68Ga]Ga-NOTA-H006的摩尔活度为6.48-54.2 GBq/µmol,放化纯度大于98%。
  • BxPC-3荷瘤小鼠microPET/CT清晰显示5T4表达;离体生物分布显示注射后60分钟肿瘤/血比值约3倍、肿瘤/肌肉比值约5倍达最高。
  • 共注射1.5 mg/kg冷H006显著降低肿瘤摄取(p<0.0001)。

局限性

  • 原文结论指出需进一步临床研究以探索其在疾病进展和伴随诊断中的临床价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Trophoblast glycoprotein, the so-called 5T4, is an oncofetal antigen expressed in many different cancers. However, no 5T4-specific radioligand is employed in the clinic for non-invasive diagnosis. Thus, the aim of the current study was to develop a PET radiotracer for imaging 5T4 expression in preclinical and clinical stages. METHODS: A VHH library was constructed by camel immunization. The specificity of the VHHs toward 5T4 antigen was screened through phage display biopanning and periplasmic extract enzyme-linked immunosorbent assay. 1,4,7-Triazacyclononane-1,4,7-triacetate acid (NOTA) derivative was conjugated to the selected VHH. After radiolabeling, microPET/CT and ex vivo biodistribution were conducted using BxPC-3 and MDA-MB-468 tumor-bearing mice. Cold VHH was co-injected with the tracer to challenge its binding in vivo. For the pilot clinical study, PET/CT images were acquired at 1 h after injection of tracer in patients with pathologically confirmed primary and metastatic tumors. RESULTS: A library with a capacity of 1.2 × 1012 colony-forming units was constructed after successful camel immunization. Nb1-40 with a median effect concentration of 0.43 nM was selected. After humanization, the resulting H006 maintained a high affinity towards 5T4. [68Ga]Ga-NOTA-H006 with the molar activities of 6.48-54.2 GBq/µmol was prepared with high radiochemical purity (> 98%). Using [68Ga]Ga-NOTA-H006, microPET/CT revealed a clear visualization of 5T4 expression in BxPC-3 tumor-bearing mice. Ex vivo biodistribution showed that the highest tumor-to-blood ratio (∼ 3-fold) and tumor-to-muscle ratio (∼ 5-fold) were achieved at 60 min post-injection. Co-injection of the cold H006 at a dose of 1.5 mg/kg significantly reduced the tumor uptake (p < 0.0001). In the pilot clinical study, [68Ga]Ga-NOTA-H006 demonstrated its capacity to map 5T4-positive lesions in humans and yielded a mean effective dose of 3.4 × 10- 2 mSv/MBq. CONCLUSIONS: [68Ga]Ga-NOTA-H006, which can visualize 5T4 expression in vivo, has been successfully developed. This opens up opportunities for non-invasively studying 5T4 expression through nuclear medicine. Further clinical investigations are warranted to explore its clinical value in disease progression and companion diagnosis.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. He Y, Tian R, Xu D, et al. Preclinical evaluation and pilot clinical study of [68Ga]Ga-NOTA-H006 for non-invasive PET imaging of 5T4 oncofetal antigen. Eur J Nucl Med Mol Imaging. 2024. PMID: 39377811. doi:10.1007/s00259-024-06941-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。